annual meeting program - American Society of Clinical Oncology

Monday, June 7, 2010
Brd. 17 Voreloxin single-agent treatment of older patients (60 years or older) with
previously untreated acute myeloid leukemia: Final results from a phase II
study with three schedules. (Abstract #6525)
R. K. Stuart, F. Ravandi Kashani, L. D. Cripe, M. B. Maris, M. A. Cooper,
S. R. Dakhil, R. M. Stone, F. Turturro, J. A. Fox, G. Michelson
Brd. 18 Final results of a phase II pharmacokinetic/pharmacodynamic (PK/PD) study
of combination voreloxin and cytarabine in patients with relapsed or
refractory acute myeloid leukemia. (Abstract #6526)
G. J. Roboz, J. E. Lancet, L. D. Cripe, F. Ravandi Kashani, A. F. List, J. A. Fox,
G. Michelson, J. E. Karp
Brd. 19 Randomized study of decitabine versus conventional care (CC) in patients
(pts) with intermediate- and high-risk acute myeloid leukemia (AML) in first or
subsequent complete remission (CR). (Abstract #6527)
F. Ravandi Kashani, J. Jorgensen, S. Faderl, J. Issa, J. Autry, G. Garcia-Manero,
G. Borthakur, X. Huang, J. E. Cortes, H. Kantarjian
Brd. 20 A randomized phase II study of sapacitabine in MDS refractory to
hypomethylating agents. (Abstract #6528)
G. Garcia-Manero, S. M. Luger, P. Venugopal, L. J. Maness, M. Wetzler,
J. K. Altman, D. Claxton, S. A. Strickland, J. H. Chiao, H. Kantarjian
Brd. 21 Evaluation of efficacy and mortality in elderly patients (pts) (70 years [yrs] or
older) with acute myeloid leukemia (AML) treated with intensive
chemotherapy (IC). (Abstract #6529)
T. M. Kadia, F. Ravandi Kashani, S. M. O’Brien, J. E. Cortes, E. Jabbour,
G. Borthakur, S. Faderl, S. Pierce, M. Brandt, H. Kantarjian
Brd. 22 Frontline azacitidine (AZA) or intensive chemotherapy (ICTx) in older AML
patients. (Abstract #6530)
C. Gardin, R. Itzykson, S. Thépot, C. Recher, A. Marfaing, O. Beyne-Rauzy,
S. Boehrer, F. Dreyfus, P. Fenaux, H. Dombret, for the GFM and ALFA Groups
Brd. 23 Treatment of older patients with de novo acute myeloid leukemia (AML) with
one or more postremission chemotherapy courses: Analysis of four CALGB
studies. (Abstract #6531)
M. R. Baer, S. L. George, B. L. Sanford, R. M. Stone, G. Marcucci, R. J. Mayer,
R. A. Larson
Brd. 24 Treatment of acute myeloid leukemia (AML) in first remission (CR1) with
unrelated donor (UD) allogeneic hematopoietic cell transplantation (HCT).
(Abstract #6532)
Q. Bashir, B. Andersson, L. De Padua Silva, G. Rondon, A. Chiattone, C. Hosing,
M. Fernandez-Vina, S. Giralt, R. E. Champlin, M. J. De Lima
401
MONDAY